Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 36%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health is well-positioned in the growing market for value-based care and population health management, as evidenced by its partnership with UPMC Health Plan and The Advisory Board Company, and its expanding suite of solutions in areas such as oncology, cardiology, and musculoskeletal care. With strong financials and a growing demand for its services, EVH has an estimated 25% revenue growth for 2027 and a de-risked adjusted EBITDA of $150 million. Despite potential risks such as utilization and new contract wins, we maintain a Buy rating on EVH due to its improved visibility and attractive valuations.

Bears say

Evolent Health is facing headwinds, with a recent $90 million increase in commercial revenue appearing unimpressive compared to their $60 million increase in Medicare. Additionally, the company is seeing decline in Medicaid and HIX business, and uncertainties surrounding Medicaid work requirements pose a significant threat. These factors, along with the company's declining margins and slow margin maturation, lead to a negative outlook for Evolent Health's stock.

Evolent Health (EVH) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 36% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 14 analysts, Evolent Health (EVH) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.